To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals
• Collaborators: H. Lundbeck A/S; Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of Schizophrenia or Schizoaffective disorder

• 18-55 years

Exclusion Criteria:

• Subjects who are acutely psychotic

• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia

• Subjects at significant risk of suicide

• Subjects with a seizure disorder